Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 36.3% in December

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totaling 95,551 shares, a decrease of 36.3% from the December 15th total of 149,941 shares. Based on an average daily volume of 547,804 shares, the short-interest ratio is presently 0.2 days. Currently, 4.0% of the shares of the company are sold short. Currently, 4.0% of the shares of the company are sold short. Based on an average daily volume of 547,804 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on VRAX shares. Zacks Research upgraded Virax Biolabs Group to a “hold” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $1.00 target price (down previously from $3.00) on shares of Virax Biolabs Group in a research report on Friday, January 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $1.00.

Virax Biolabs Group Trading Up 0.6%

Shares of VRAX stock traded up $0.00 on Friday, reaching $0.32. The company’s stock had a trading volume of 123,457 shares, compared to its average volume of 330,743. Virax Biolabs Group has a 12-month low of $0.30 and a 12-month high of $2.33. The stock’s 50 day simple moving average is $0.42 and its 200-day simple moving average is $0.61.

Virax Biolabs Group (NASDAQ:VRAX) last announced its earnings results on Tuesday, December 2nd. The company reported ($0.27) earnings per share for the quarter. The business had revenue of $0.00 million during the quarter.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.